Currently, there are several experimental trials based on the targeting of FGFR3 signaling for the treatment of ACH, by using small chemical inhibitors of FGFR3 catalytic activity, or downstream biomolecule-targeting pathways of FGFR3 signaling [48,49]. Here, FGFR3 is linked to achondroplasia.